---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000091"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-05-30T23:59:59+00:00"
generated_at: "2026-05-20T04:14:29.270015+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics enrolls first patient in Phase 3 AURORA trial of Descartes-08 for myasthenia gravis

## Summary
- First participant enrolled in randomized, placebo-controlled Phase 3 AURORA trial of Descartes-08 (CAR-T) in ~100 patients with AChR Ab+ myasthenia gravis.
- Descartes-08 is administered outpatient without preconditioning chemotherapy; primary endpoint is proportion with MG-ADL improvement ≥3 points at Month 4.
- Phase 2b data cited: average 4.8-point MG-ADL reduction at Month 12; in biologic-naive subgroup 7.1-point reduction and 57% minimal symptom expression.
- Safety profile consistent with prior data; continues to support outpatient administration without integrating vectors or conditioning chemotherapy.

## SEC filing metadata
- accession: 0001453687-25-000091
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000091/0001453687-25-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000091/rnac-20250530.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000091
- JSON: https://secwatch.observer/filing/0001453687-25-000091.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.